Evidence map›Paper›PMID 30696949›Full record

Trial reportLeukemia2019

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04217967 (A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04217967 phase4completednot on this map

A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma

TypeinterventionalSponsorPeking Union Medical College HospitalRan2019 to 2024Enrolled211ConditionsMultiple MyelomaArmsIxazomib, Lenalidomide
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Lenalidomide use in multiple myeloma (Review).Molecular and clinical oncology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Drug Repurposing by Tumor Tissue Editing.Frontiers in oncology · 2022
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Shaji K KumarMayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.ORCID http://orcid.org/0000-0001-5392-9284
Jesus G BerdejaSarah Cannon Research Institute, Nashville, TN, USA.
Ruben NiesvizkyMyeloma Center, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Sagar LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Jacob P LaubachDana-Farber Cancer Institute, Boston, MA, USA.
Mehdi HamadaniWest Virginia University, Mary Babb Randolph Cancer Center, Morgantown, WV, USA.
A Keith StewartMayo Clinic College of Medicine, Scottsdale, AZ, USA.
Parameswaran HariDivision of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Vivek RoyMayo Clinic, Jacksonville, FL, USA.
Robert VescioCedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Jonathan L KaufmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Deborah BergMillennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA.
Eileen LiaoMillennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA.
S Vincent RajkumarMayo Clinic, Rochester, MN, USA.
Paul G RichardsonDana-Farber Cancer Institute, Boston, MA, USA.
Mayo Clinic in Arizona · USDana-Farber Cancer Institute · USEmory University · USBiogen (United States) · USCedars-Sinai Medical Center · USMedical College of Wisconsin · USNewYork–Presbyterian Hospital · USSarah Cannon · USTakeda (United States) · USWest Virginia University · USWinnMed · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance in NDMM patients. Of 65 enrolled patients, 53 received ixazomib 4 mg (days 1, 8, and 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, and 22) for up to twelve 28-day induction cycles. Twenty-three patients discontinued induction for stem cell transplantation (SCT). In the remaining 42 patients, overall response rate was 80%, including 63% ≥very good partial response (VGPR) and 32% complete responses. At a median follow-up of 56 months, median progression-free survival (PFS) was 35.4 months in the total population. Twenty-five patients received ixazomib maintenance; eight deepened their response (76% ≥VGPR), and median PFS was 37.2 months in this subgroup. Nine of 42 patients who did not proceed to SCT (14% of total population) had an adverse event requiring discontinuation. Ixazomib (median ≥ 96%) and lenalidomide (median 88-94%) relative dose intensities were maintained throughout treatment. Weekly IRd, followed by ixazomib maintenance, was highly active with acceptable toxicity, enabling long-term administration with no evidence of cumulative toxicities.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBoron CompoundsDexamethasoneFemaleFollow-Up StudiesGlycineHumansLenalidomideMaintenance ChemotherapyMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaBoron CompoundsDexamethasoneGlycineixazomibLenalidomide

Identifiers

PMID30696949
PMCPMC6755968
OpenAlexW2912018514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.